Breast Invasive Ductal Carcinoma Diagnosis with A Three-Mirna Panel in Serum

Chen, Xuan; Li, Xinji; Wang, Jingyao; Zhao, Liwen; Peng, Xiqi; Zhang, Chunduo; Liu, Kaihao; Huang, Guoxin; Lai, Yongqing

doi:10.2217/bmm-2020-0785

Cited by 12 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examination of miRNAs for specific fractions can significantly increase both the sensitivity and specificity of selected circulating miRNAs as noninvasive biomarkers [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 ].…”

Section: Circulating Mirnamentioning

confidence: 99%

miRNAs in Cancer (Review of Literature)

Smolarz

Durczyński

Romanowicz

et al. 2022

IJMS

136

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short, noncoding, single-stranded RNA molecules that regulate gene expression at the post-transcriptional level by binding to mRNAs. miRNAs affect the course of processes of fundamental importance for the proper functioning of the organism. These processes include cell division, proliferation, differentiation, cell apoptosis and the formation of blood vessels. Altered expression of individual miRNAs has been shown in numerous cancers, which may indicate the oncogenic or suppressor potential of the molecules in question. This paper discusses the current knowledge about the possibility of using miRNA as a diagnostic marker and a potential target in modern anticancer therapies.

show abstract

Section: Circulating Mirnamentioning

confidence: 99%

miRNAs in Cancer (Review of Literature)

Smolarz

Durczyński

Romanowicz

et al. 2022

IJMS

136

View full text Add to dashboard Cite

show abstract

“…Typical miRNAs, which are highly correlated with cancer based on the KEGG pathway analysis, were identified based on the human miRNA database ( Figure S4 ). KEGG enrichment analysis revealed that many of these down-regulation miRNAs including miR-125a-5p [ 53 , 54 ], miR-34a-5p [ 55 ], miR-132-3p [ 56 ], and miR-148b-3p, were BC biomarkers highly correlated with PEG-ReS2-based PTT. In addition, we found 37 up-regulation miRNAs ( Figure 6 e and Figure S5 ), including miR-133a-3p [ 57 , 58 ], miR-200c-5p, miR-9-3p, and miR-150-3p, which were also highly correlated with PEG-ReS 2 -based PTT.…”

Section: Resultsmentioning

confidence: 99%

Promising Colloidal Rhenium Disulfide Nanosheets: Preparation and Applications for In Vivo Breast Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

Photothermal therapy (PTT) has become an important therapeutic strategy in the treatment of cancer. However, exploring novel photothermal nanomaterials with satisfactory biocompatibility, high photothermal conversion efficiency, and efficient theranostic outcomes, remains a major challenge for satisfying clinical application. In this study, poly-ethylene glycol modified rhenium disulfide (PEG-ReS2) nanosheets are constructed by a simple-liquid phase exfoliation method. The PEG-ReS2 nanosheets were demonstrated to have good solubility, good biocompatibility, low toxicity, and strong capability of accumulating near-infrared (NIR) photons. Under 808 nm laser irradiation, the PEG-ReS2 nanosheets were found to have an excellent photothermal conversion efficiency (PTCE) of 42%. Moreover, the PEG-ReS2 nanosheets were demonstrated to be ideal photothermal transduction agents (PTAs), which promoted rapid cancer cell death in vitro and efficiently ablated tumors in vivo. Interestingly, the potential utility of up-regulation or down-regulation of miRNAs was proposed to evaluate the therapeutic outcomes of PEG-ReS2 nanosheets. The expression levels of a set of miRNAs in tumor-bearing mice were restored to normal levels after PTT therapy with PEG-ReS2 nanosheets. Both down-regulation miRNAs (miR-125a-5p, miR-34a-5p, miR-132-3p, and miR-148b-3p) and up-regulation miRNAs (miR-133a-3p, miR-200c-5p, miR-9-3p, and miR-150-3p) were suggested to be important clinical biomarkers for evaluating therapeutic outcomes of breast cancer-related PTT. This work highlights the great significance of PEG-ReS2 nanosheets as therapeutic nanoagents for cancer therapy.

show abstract

“…Chen and Li established a serum three-miRNA panel (AUC = 0.880) that enhances the diagnostic e cacy of breast invasive ductal carcinoma. Therefore, the serum three-miRNA panel, including miR-9-5p, miR-34b-3p, and miR-146a-5p, holds tremendous potential as non-invasive biomarkers for diagnosing breast invasive ductal carcinoma [40] .…”

Section: Discussionmentioning

confidence: 99%

Plasma exosomal miR-125b-5p and miR-143-3p have potential to diagnose breast cancer

Fan,

Li,

Huang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Breast cancer (BC) is the most common malignancy in women, posing a serious health risk. Exosomal microRNA (miRNA) has emerged as a promising cancer biomarker. Despite its potential, research on exosomal miRNA in BC remains limited. This study aims to identify plasma exosomal miRNAs for diagnosing BC. Methods Firstly, plasma exosomal miRNA sequencing was conducted on 45 BC patients and 5 healthy controls, followed by Differential Expression Analysis to screen for differentially expressed miRNAs. The diagnostic value of these miRNAs was assessed using receiver operating characteristic (ROC) curves. Subsequent analysis of candidate miRNAs was carried out in the TCGA database. Target genes of differentially expressed miRNAs were predicted using online databases, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. Finally, a ceRNA network was constructed using Cytoscape. Results Our analysis indicates that, compared to normal controls, plasma exosomal miR-125b-5p and miR-143-3p are significantly downregulated in BC patients. The area under the curve (AUC) for exosomal miR-125b-5p is 0.951 (sensitivity 91.1%, specificity 100%), and the AUC for exosomal miR-143-3p is 0.924 (sensitivity 86.7%, specificity 100%). In the TCGA database, the expression of miR-125b-5p and miR-143-3p is downregulated in BC tissues compared to adjacent normal tissues. Target gene prediction and enrichment analyses reveal pathways closely associated with BC occurrence. Conclusions Our results demonstrate that plasma exosomal miR-125b-5p and miR-143-3p can distinguish between BC patients and normal controls. The downregulation of plasma exosomal miR-125b-5p and miR-143-3p may potentially serve as a marker for the occurrence of BC.

show abstract

Breast Invasive Ductal Carcinoma Diagnosis with A Three-Mirna Panel in Serum

Cited by 12 publications

References 33 publications

miRNAs in Cancer (Review of Literature)

miRNAs in Cancer (Review of Literature)

Promising Colloidal Rhenium Disulfide Nanosheets: Preparation and Applications for In Vivo Breast Cancer Therapy

Plasma exosomal miR-125b-5p and miR-143-3p have potential to diagnose breast cancer

Contact Info

Product

Resources

About